|
1）Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000; 55: 16-23
|
|
|
|
2）Burns TM. History of outcome measures for myasthenia gravis. Muscle Nerve. 2010; 42: 5-13
|
|
|
|
|
|
3）Farrugia ME, Robson MD, Clover L, et al. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthe-nia gravis. Brain. 2006; 129: 1481-92
|
|
|
|
|
|
4）Farrugia ME, Harle HD, Carmichael C, et al. The oculobulbar facial respiratory score is a tool to assess bulbar function in myasthenia gravis patients. Muscle Nerve. 2011; 43: 329-34
|
|
|
|
|
|
5）Sanders DB, Tucker-Lipscomb B, Massey JM. A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score. Ann N Y Acad Sci. 2003; 998: 440-4
|
|
|
|
|
|
6）Wolfe GI, Barohn RJ, Sanders DB, et al. Muscle study Group. Comparison of outcome measures from a trial of mycophenolate mofetil in myasthe-nia gravis. Muscle Nerve. 2008; 38: 1429-33
|
|
|
|
|
|
7）Kulkantrakorn K, Sawanyawisuth K, Tiamkao S. Factors correlating quality of life in patients with myasthenia gravis. Neurol Sci. 2010; 31: 571-3
|
|
|
|
|
|
8）Twork S, Wiesmeth S, Klewer1 J, et al. Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes. 2010; 8: 129
|
|
|
|
|
|
9）Wolfe GI, Herbelin L, Nations SP, et al. Myasthenia gravis activities of daily living profile. Neurology. 1999; 52: 1487-9
|
|
|
|
|
|
10）Muppidi S, Wolfe GI, Conaway M, et al. MG-ADL: still a relevant outcome measure. Muscle Nerve. 2011; 44: 727-31
|
|
|
|
|
|
11）Burns TM, Grouse CK, Conaway MR, et al. MG composite and MG-QOL15 study group. Con-struct and concurrent validation of the MG-QOL15 in the practice setting. Muscle Nerve. 2010; 41: 219-26
|
|
|
|
|
|
12）Burns TM, Conaway MR, Cutter GR, et al. Muscle Study Group. Less is more, or almost as much. The development of a fifteen-item quality-of-life instrument for patient with myasthenia gravis. Muscle Nerve. 2008; 38: 957-63
|
|
|
|
|
|
13）Burns TM, Grouse CK, Wolfe GI, et al. MG Composite and MG-QOL15 Study Group. The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis. Muscle Nerve. 2011; 43: 14-8
|
|
|
|
|
|
14）Burns TM, Conway MR, Sanders DB; MG composite and MG-QOL15 Study Group. The MG composite: a valid and reliable outcome measure for myasthenia gravis. Neurology. 2010; 74: 1434-40
|
|
|
|
|
|
15）Burns TM, Conaway MR, Cutter GR, et al. The construction of an efficient evaluative instrument for myasthenia gravis: the MG Composite. Muscle Nerve. 2008; 38: 1553-62
|
|
|
|
|
|
16）槍沢公明，増田眞之，鈴木重明，他．重症筋無力症患者QOL調査: MG-QOL15日本語版の作成とQOL阻害因子の検討．免疫性神経疾患に関する調査研究班 平成23年度班会議抄録集．2012. p.90-1
|
|
|
|
|
|
17）Masuda M, Utsugisawa K, Suzuki S, et al. The MG-QOL15 Japanese version: validation and association with clinical factors. Muscle Nerve. 2012; 46: 166-73
|
|
|
|
|
|
18）Palace J, Newsom-Davis J, Lecky B; Myasthenia Gravis Study Group. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology. 1998; 50: 1778-83
|
|
|
|
|
|
19）Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. Mycophenolate mofetil for myasthenia gravis. Ananalysis of efficacy, safety, and tolerability. Neurology. 2003; 61: 1438-40
|
|
|
|
|
|
20）Kawaguchi N, Yoshiyama Y, Nemoto Y, et al. Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis. Curr Med Res Opin. 2004; 20: 1269-73
|
|
|
|
|
|
21）Ponsetti JM, Azem J, Fort JM, et al. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology. 2005; 64: 1641-3
|
|
|
|
|
|
22）Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008; 71: 400-6
|
|
|
|
|
|
23）Aban IB, Wolfe GI, Cutter GR, et al; Mgtx Advisory Committee. The MGTX experience. Challenges in planning and executing an international, multicenter clinical trial. J Neuroimmunol. 2008; 201-202: 80-4
|
|
|
|
|